Christopher A Jankowski

🔥It's published 🔥 The first ever RCT combination therapy for Stenotrophomonas maltophelia infections Efficacy of combination therapy with minocycline for treating Stenotrophomonas maltophilia infections 🔺Adjunctive minocycline did not significantly reduce 28-day-mortality (n = 24/55[43.6%] vs n = 22/57[38.6%], P = 0.590) #IDXposts @drgabx academic.oup.com/jacamr/arti…

Excellent Review! 🆕💥🔴Daptomycin for enterococcal bloodstream infections and endocarditis: reconciling clinical evidence, susceptibility testing, and regulatory frameworks #idxposts #IEWiki thelancet.com/journals/lanin…

🆕💥Just published 🆕💥 Histoplasmosis in Adults, Children, and Pregnant Individuals Consensus Statement: Initial Antifungal Treatment of Severe Histoplasmosis #idxposts idsociety.org/practice-guide…

🔥🔥Back online🔥🔥 IDSA/ESCMID 2026 Guidelines on Staphylococcus aureus Bacteremia: Risk Stratification, Diagnostic Evaluation, and Management of Adults and Children Part-1 #IDXposts idsociety.org/practice-guide…

🚫Very important 🚫 Recommendation 4.6 Cefazolin does not share any side chains with the currently available penicillins and can be used in cases of suspected or proven immediate type allergy to a penicillin*, irrespective of severity or time elapsed since the index reaction (Strong recommendation, moderate quality of evidence – GRADE) *: With the exception of patients with severe anaphylaxis (e.g. anaphylactic shock), in which case the panel recommends seeking expert evaluation first)

🔥Just published A Systematic Review and Network Meta-Analysis 15 cohorts were included Comparative Efficacy and Safety of Antibacterial Regimens for Severe Stenotrophomonas maltophilia Infections 🔺This is the most comprehensive network meta-analysis evaluating both the short-term clinical efficacy and long-term survival outcomes of targeted antimicrobial regimens for SMA infections 🔺The network meta-analysis revealed a notable discordance between primary efficacy and survival benefits 🔺A “survival paradox” exists in SMA treatment: tigecycline yields superior initial response without improving survival, whereas levofloxacin provides the most significant survival benefit 🔺Surprisingly: Levofloxacin ranked highest with a SUCRA value of 91.3% (PrBest [Probability of being best] =75.8%), establishing it as the most favorable option for patient survival. 🔺Strikingly, the traditional preferred agent, TMP-SMX, had the lowest probability of being effective, ranking definitively last with a SUCRA value of 2.4% 🔺Levofloxacin significantly improved survival versus TMP-SMX (OR=2.01, 95%CI 1.16-3.47, P=0.012) 🔺Minocycline serves as a highly reliable and effective alternative across all endpoints. Given the rising resistance and unacceptable toxicity profile The principal findings challenge the traditional paradigm that positions TMP-SMX as the undisputed preferred therapy. @drgabx @BradSpellberg ICYMI #idxposts ijidonline.com/article/S1201…

The most surprising finding, fidaxomicin FAILED to demonstrate superiority over standard vancomycin, challenging the long-held expectation that it is superior to vancomycin for rCDI. #IDXposts

🔥🔥IDSA AMR Guidance 2026🔥🔥 🔺Notable Updates from the 2024 IDSA AMR Guidance Document IDSA 2026 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections 🔺ESBL, AmpC Enterobacterales 🔺CRE 🔺DTR P. aeruginosa 🔺CRAB 🔺Stenotrophomonas maltophilia Including updates in antimicrobial selection, dosing strategies, and management approaches. 🔺Meropenem dosing update: individualized dosing approach (1–2 g IV q8h) with higher doses considered in selected clinical scenarios. Info inspired / credit to @RabeaAgeeli , #IDXposts idsociety.org/practice-guide…

🆕💥🟢Systematic review and meta-analysis Effect of high-dose versus standard-dose influenza vaccines on hospitalisation outcomes and mortality in older adult #IDXposts thelancet.com/journals/lanhl…

Guidelines recommend liposomal amphotericin B (L-AMB) at 5–10 mg/kg/day as first-line therapy for invasive mucormycosis, but whether doses exceeding 5–6 mg/kg/day improve outcomes enough to justify added nephrotoxicity and cost remains unclear! 🆕💥🔴Does the Evidence Support High-Dose Liposomal Amphotericin B in the Treatment of Mucormycosis? #idxposts academic.oup.com/jid/article…